Chinese onshore investors raised their investments in Hong Kong-listed drug makers through the cross-border trading link over the past week, as a wave of out-licensing deals between Chinese pharmaceutical firms and global partners rolls on. The Hang Seng Southbound Connect Hong Kong Innovative Drug Index, which tracks around 40 of the largest Hong Kong-listed Chinese drug manufacturers, biotech researchers and AI-driven drug developers by market capitalisation, rose about 9 per cent between…
You must log in or # to comment.